These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 30043207

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855
    [Abstract] [Full Text] [Related]

  • 3. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y.
    Ai Zheng; 2006 Apr 26; 25(4):495-500. PubMed ID: 16613688
    [Abstract] [Full Text] [Related]

  • 4. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, Cai L, Wu YD, Yao Q, Zhao XC, Mao WD, Jiang AM, Chen SS, Yang SE, Wang SS, Wang JH, Pan YY, Ren BY, Chen YJ, Ouyang LZ, Lei KJ, Gao JH, Huang WH, Huang Z, Shou T, He YL, Cheng J, Sun Y, Li WM, Cui SD, Wang X, Rao ZG, Ma H, Liu W, Wu XY, Shen WX, Cao FL, Xiao ZM, Wu B, Tian SY, Meng D, Shen P, Wang BY, Wang Z, Zhang J, Wang L, Hu XC.
    Breast Cancer Res Treat; 2018 Apr 26; 168(2):389-399. PubMed ID: 29230663
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y.
    Thorac Cancer; 2022 Jan 26; 13(1):117-125. PubMed ID: 34791805
    [Abstract] [Full Text] [Related]

  • 8. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L.
    Zhonghua Zhong Liu Za Zhi; 2016 Jan 26; 38(1):23-7. PubMed ID: 26796802
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J.
    Clin Lung Cancer; 2016 Mar 26; 17(2):119-27. PubMed ID: 26781346
    [Abstract] [Full Text] [Related]

  • 10. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
    Zou D, Guo M, Zhou Q.
    BMC Cancer; 2021 Jun 02; 21(1):661. PubMed ID: 34078317
    [Abstract] [Full Text] [Related]

  • 11. Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
    Sun J, Bai H, Wang Z, Duan J, Li J, Guo R, Wang J.
    Thorac Cancer; 2020 Mar 02; 11(3):713-722. PubMed ID: 32020764
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
    Huang X, Li S, Shi W, Wang Y, Wan X, He J, Xu Y, Zhang W, Shi X, Chen R, Xu L, Zha X, Wang J.
    Br J Clin Pharmacol; 2023 Jan 02; 89(1):372-379. PubMed ID: 36001055
    [Abstract] [Full Text] [Related]

  • 14. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia.
    Wu FP, Wang J, Wang H, Li N, Guo Y, Cheng YJ, Liu Q, Yang XR.
    Exp Ther Med; 2015 Mar 02; 9(3):761-765. PubMed ID: 25667625
    [Abstract] [Full Text] [Related]

  • 15. Pegylated recombinant human granulocyte colony-stimulating factor for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy: a prospective study.
    You J, Yuan Y, Gu X, Wang W, Li X.
    BMC Cancer; 2024 Jul 12; 24(1):833. PubMed ID: 38997665
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y, Liang Y, Li H.
    BMC Cancer; 2023 Jul 26; 23(1):702. PubMed ID: 37495949
    [Abstract] [Full Text] [Related]

  • 17. [Clinical observation of the salvage therapy using pegylated recombinant human granulocyte colony stimulating factor for grade IV neutropenia induced by concurrent chemoradiotherapy].
    Wu F, Wang H, Li N, Guo Y, Cheng Y, Liu Q, Yang X, Wan X, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2014 Sep 26; 36(9):708-12. PubMed ID: 25564064
    [Abstract] [Full Text] [Related]

  • 18. [A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer].
    Jiang ZF, Xu FR, Fan J, Li BJ, Gao JN, Hu JW, Wang XJ, Zhang YQ, Wang JH, Li F, Liu Q, Liu YH, Wang S, Wang YS, Ouyang QC, Hu B, Sun GP, Zhang Y, Zang AM, Fan PZ, Wu CP, Liu J, Zhang HW, Wang W, Hu XC, Tang LL, Zhang J, Bao YY, Geng CZ, Sun Q, Zhang F, Yin YM, Jiang HC, An YH.
    Zhonghua Yi Xue Za Zhi; 2018 Apr 24; 98(16):1231-1235. PubMed ID: 29747310
    [Abstract] [Full Text] [Related]

  • 19. A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: An interim analysis.
    Huang J, Lu S, Wang J, Jiang L, Luo X, He X, Wu Y, Wang Y, Zhu X, Chen J, Tang Y, Chen K, Tian X, Shi B, Guo L, Zhu J, Sun F, Zhen Z, Zhang Y.
    Cancer Med; 2023 Jul 24; 12(13):14130-14137. PubMed ID: 37183837
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.